Neither vortioxetine dose achieved a statistically significant improvement over placebo on the primary endpoint ( least-squares mean differencestandard error from placebo : -0.870.803 [ p = 0.279 ] for 2.5 mg and -0.810.791 [ p = 0.306 ] for 10mg vortioxetine ) or on any secondary efficacy endpoints .